Bayer is putting in place measures which it claims will cut down on administration and promote innovation.
The German group’s pharmaceutical business, previously Bayer Schering Pharma, will operate as a division called Bayer HealthCare Pharmaceuticals under the leadership of Andreas Fibig, and its headquarters will remain in Berlin. Also, as from March, Andreas Busch and Kemal Malik, respectively heads of pharma research and pharma development, will report directly to Joerg Reinhardt, the boss of Bayer HealthCare (BHC).
Furthermore, in the USA, BHC plans to consolidate the four east coast sites it currently maintains into one this year, as part of its efficiency programme. The new centre for 2,500 people employees will be built in the vicinity of one of the existing sites in the New Jersey/New York region.
Dr Reinhardt said that BHC has good potential for growth in all of its divisions and “to optimally exploit this potential, we must further consolidate the existing resources, shorten the decision-making paths and make our structures leaner”. He added that “this will enable us to sustainably finance our investment in growth and innovation”.
He concluded by saying that the reorganisation “is the logical next step for more innovation and less administration”.
